13 March 2026
13 March 2026
PsiQuantum will work with the National Cancer Center Japan to develop fault-tolerant algorithms and quantum applications.
The study will assess the tolerability, safety, maximum tolerated dose, and the recommended Phase II dose of PLT012.
The study was carried out at 24 clinical sites across the UK and included 303 participants.
The VISERA ELITE III supports various specialities, including general surgery, arthroscopy, and ENT.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
